AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Maviret, an oral pangenotypic direct-acting antiviral therapy for the treatment of acute hepatitis C infection in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, Maviret would be indicated for both acute and chronic hepatitis C infection in the European Union.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey
- AbbVie’s NAAVIGATE Trial Targets One-Time Gene Therapy for Diabetic Retinopathy
- AbbVie Earnings Call Highlights Growth Amid Transition
- AbbVie price target lowered to $235 from $236 at Evercore ISI
- 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26